Disciplined Investors L.L.C. Invests $1.03 Million in Novo Nordisk A/S $NVO

Disciplined Investors L.L.C. acquired a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 20,233 shares of the company’s stock, valued at approximately $1,029,000.

A number of other hedge funds also recently made changes to their positions in NVO. Revolve Wealth Partners LLC raised its position in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after acquiring an additional 200 shares during the last quarter. AQR Capital Management LLC increased its holdings in Novo Nordisk A/S by 21.0% in the first quarter. AQR Capital Management LLC now owns 62,099 shares of the company’s stock worth $4,312,000 after purchasing an additional 10,758 shares in the last quarter. Sivia Capital Partners LLC increased its holdings in Novo Nordisk A/S by 18.2% in the second quarter. Sivia Capital Partners LLC now owns 10,320 shares of the company’s stock worth $712,000 after purchasing an additional 1,587 shares in the last quarter. Invesco Ltd. increased its holdings in Novo Nordisk A/S by 26.3% in the second quarter. Invesco Ltd. now owns 419,691 shares of the company’s stock worth $28,967,000 after purchasing an additional 87,467 shares in the last quarter. Finally, Gamco Investors INC. ET AL bought a new stake in Novo Nordisk A/S in the second quarter worth approximately $314,000. 11.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on NVO. Zacks Research upgraded Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, March 10th. Morgan Stanley upgraded Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 target price for the company in a report on Tuesday, March 3rd. Jefferies Financial Group upgraded Novo Nordisk A/S from an “underperform” rating to a “hold” rating in a report on Thursday, February 12th. Weiss Ratings downgraded Novo Nordisk A/S from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday, April 22nd. Finally, The Goldman Sachs Group reiterated a “neutral” rating and issued a $41.00 target price (down from $63.00) on shares of Novo Nordisk A/S in a report on Monday, March 2nd. Four equities research analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $65.56.

Novo Nordisk A/S Trading Down 2.0%

NYSE NVO opened at $42.06 on Thursday. The company has a market cap of $187.78 billion, a price-to-earnings ratio of 9.87, a P/E/G ratio of 3.83 and a beta of 0.78. Novo Nordisk A/S has a 52 week low of $35.12 and a 52 week high of $81.44. The business has a 50 day moving average price of $41.35 and a 200-day moving average price of $46.24. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. The firm had revenue of $10.85 billion during the quarter. Novo Nordisk A/S had a return on equity of 63.31% and a net margin of 37.23%. As a group, equities analysts expect that Novo Nordisk A/S will post 3.46 earnings per share for the current fiscal year.

Key Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk launched the Wegovy pill in the UAE, marking its first market outside the U.S. and signaling the start of a broader international rollout for its obesity franchise. Reuters article
• Positive Sentiment: Novi Health announced a partnership with Novo Nordisk to expand structured weight-care support in Singapore, which could help improve patient access and treatment adoption in another growth market. Yahoo Finance article
• Positive Sentiment: Danske Bank raised Denmark’s GDP forecast to 3.7%, citing export strength supported by demand for Novo Nordisk products, underscoring the company’s importance to the Danish economy. Financial Post article
• Neutral Sentiment: Commentary suggested there may be “light at the end of the tunnel” for Novo Nordisk, but it was opinion-based rather than a new fundamental update. Motley Fool article
• Negative Sentiment: Eli Lilly won back CVS Health, reversing part of Novo Nordisk’s advantage in GLP-1 access and highlighting intensifying competition in the obesity drug market. MarketBeat article
• Negative Sentiment: ASML’s surge to record valuation drew attention to Novo Nordisk’s prior peak as Europe’s most valuable stock, reinforcing how far NVO has fallen from its high-water mark. Yahoo Finance article

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.